IRulya Therapeutics Inc.: BALYASNY ASSET MANAGEMENT L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Balyasny Asset Management L.P. amended its Schedule 13G stake filing for IRulya Therapeutics Inc., disclosing the change to the SEC under accession number 0001172661-26-005046. The filing updates the hedge fund's previously reported position in the biotech company, though the amended document did not specify a revised share count or percentage in the headline disclosure. The move matters because 13G amendments signal shifts in passive or institutional ownership that can influence investor sentiment around smaller-cap biotech names. Investors will watch for the full filing details to confirm whether Balyasny increased, trimmed or maintained its stake in IRulya.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
IRulya Therapeutics Inc., Balyasny Asset Management L.P.